Targeting glutamine dependence with DRP‐104 inhibits proliferation and tumor growth of castration‐resistant prostate cancer

Author:

Moon David1ORCID,Hauck J. Spencer1ORCID,Jiang Xue1,Quang Holly2ORCID,Xu Lingfan3,Zhang Fan1,Gao Xia24,Wild Robert5,Everitt Jeffrey I.1,Macias Everardo1,He Yiping1,Huang Jiaoti1

Affiliation:

1. Department of Pathology Duke University School of Medicine Durham North Carolina USA

2. Department of Molecular and Cellular Biology Baylor College of Medicine Houston Texas USA

3. Urology Department First Affiliated Hospital of Anhui Medical University Hefei China

4. Department of Pediatrics Children's Nutrition Research Center, Baylor College of Medicine Houston Texas USA

5. Dracen Pharmaceuticals, Inc. San Diego California USA

Abstract

AbstractBackgroundProstate cancer (PCa) continues to be one of the leading causes of cancer deaths in men. While androgen deprivation therapy is initially effective, castration‐resistant PCa (CRPC) often recurs and has limited treatment options. Our previous study identified glutamine metabolism to be critical for CRPC growth. The glutamine antagonist 6‐diazo‐5‐oxo‐l‐norleucine (DON) blocks both carbon and nitrogen pathways but has dose‐limiting toxicity. The prodrug DRP‐104 is expected to be preferentially converted to DON in tumor cells to inhibit glutamine utilization with minimal toxicity. However, CRPC cells' susceptibility to DRP‐104 remains unclear.MethodsHuman PCa cell lines (LNCaP, LAPC4, C4‐2/MDVR, PC‐3, 22RV1, NCI‐H660) were treated with DRP‐104, and effects on proliferation and cell death were assessed. Unbiased metabolic profiling and isotope tracing evaluated the effects of DRP‐104 on glutamine pathways. Efficacy of DRP‐104 in vivo was evaluated in a mouse xenograft model of neuroendocrine PCa, NCI‐H660.ResultsDRP‐104 inhibited proliferation and induced apoptosis in CRPC cell lines. Metabolite profiling showed decreases in the tricarboxylic acid cycle and nucleotide synthesis metabolites. Glutamine isotope tracing confirmed the blockade of both carbon pathway and nitrogen pathways. DRP‐104 treated CRPC cells were rescued by the addition of nucleosides. DRP‐104 inhibited neuroendocrine PCa xenograft growth without detectable toxicity.ConclusionsThe prodrug DRP‐104 blocks glutamine carbon and nitrogen utilization, thereby inhibiting CRPC growth and inducing apoptosis. Targeting glutamine metabolism pathways with DRP‐104 represents a promising therapeutic strategy for CRPC.

Publisher

Wiley

Subject

Urology,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3